FDA has taken another step to further foster biologics competition with the approval of 25th biosimilar, Abrilada (adalimumab - afzb), a biosimilar to Humira.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/355lx0c
Tuesday, March 24, 2020
March 25, 2020 at 03:25AM Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment